1. Home /
    2. Altai Protocol Library /
  2. New Reference: Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Reference: Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

New Reference: Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia
Study:
  • Double-blind, randomized, placebo-controlled, phase 3 trial
  • Newly diagnosed IDH1-mutated acute myeloid leukemia
  • Ineligible for intensive induction chemotherapy
  • Oral ivosidenib and azacitidine (N:72) or placebo and azacitidine (N:74)
Efficacy:
  • HR for EFS 0.33; [0.16-0.69, P:0.002]
  • 12 months EFS: 37% vs 12%
  • Median OS: 24.0 vs 7.9 months
Safety:
  • Grade >= 3 AEs: febrile neutropenia (28% vs. 34%), neutropenia (27% vs. 16%)
  • Any grade bleeding 41% vs 29%

N Engl J Med 2022 Apr 21;386(16):1519-1531.

Montesinos, Pau et al. “Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.

https://doi.org/10.1056/nejmoa2117344

Reviewed by Hasan Çağrı Yıldırım, MD on May 30, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More